ArticleScientific reports2017
Identification of candidate diagnostic serum biomarkers for Kawasaki disease using proteomic analysis.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 64 citations in OpenAlex.
- Mapping Drivers of Coronary Endothelial Activation and Endothelial-to-Mesenchymal Transition through Mimicking of Multimediator Inflammation in Kawasaki Disease Context.ACR open rheumatology · 2025Article
- Plasma Exosomal-Derived SERPINA1 and GNAI2 Downregulation as Potential Diagnostic Biomarkers of Kawasaki Disease with Coronary Artery Aneurysms.International journal of molecular sciences · 2025Article
- Serum Olink Targeted Proteomics Identifies IL-17A as a Prospective Inflammatory Marker for the Prediction and Diagnosis of Kawasaki Disease.Journal of inflammation research · 2025Article
- Kawasaki disease: insights into the roles of T cells.Frontiers in immunology · 2025Review
- Lysine lactylation analysis of proteins in the heart of the Kawasaki disease mouse model.Frontiers in cell and developmental biology · 2025Article
- Proteomics appending a complementary dimension to precision oncotherapy.Computational and structural biotechnology journal · 2024Review
- Advances in omics data for eosinophilic esophagitis: moving towards multi-omics analyses.Journal of gastroenterology · 2024Review
- Article
- Serum levels of PDGF-CC as a potential biomarker for the diagnosis of Kawasaki disease.Italian journal of pediatrics · 2024Article
- Transcriptome meta-analysis of Kawasaki disease in humans and mice.Frontiers in pediatrics · 2024Article
- The disruptive role of LRG1 on the vasculature and perivascular microenvironment.Frontiers in cardiovascular medicine · 2024Review
- Neurological involvement, immune response, and biomarkers in Kawasaki disease along with its pathogenesis, therapeutic and diagnostic updates.F1000Research · 2023Review
- Kawasaki disease without changes in inflammatory biomarkers: A case report.World journal of clinical cases · 2022Article
- Characterization of serum protein expression profiles in the early sarcopenia older adults with low grip strength: a cross-sectional study.BMC musculoskeletal disorders · 2022Article
- An Immunological Axis Involving Interleukin 1β and Leucine-Rich-α2-Glycoprotein Reflects Therapeutic Response of Children with Kawasaki Disease: Implications from the KAWAKINRA Trial.Journal of clinical immunology · 2022Article
- Review
- Improper Proteostasis: Can It Serve as Biomarkers for Neurodegenerative Diseases?Molecular neurobiology · 2022Review
- An atypical case of Kawasaki disease with severe pneumonia in a neonate.BMC pediatrics · 2022Article
- In-Depth Serum Proteomics by DIA-MS withACS omega · 2022Article
- LRG1: an emerging player in disease pathogenesis.Journal of biomedical science · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kawasaki disease (KD) is a systemic vasculitis and childhood febrile disease that can lead to cardiovascular complications. The diagnosis of KD depends on its clinical features, and thus it is sometimes difficult to make a definitive diagnosis. In order to identify diagnostic serum biomarkers for KD, we explored serum KD-related proteins, which differentially expressed during the acute and recovery phases of two patients by mass spectrometry (MS). We identified a total of 1,879 proteins by MS-based proteomic analysis. The levels of three of these proteins, namely lipopolysaccharide-binding protein (LBP), leucine-rich alpha-2-glycoprotein (LRG1), and angiotensinogen (AGT), were higher in acute phase patients. In contrast, the level of retinol-binding protein 4 (RBP4) was decreased. To confirm the usefulness of these proteins as biomarkers, we analyzed a total of 270 samples, including those collected from 55 patients with acute phase KD, by using western blot analysis and microarray enzyme-linked immunosorbent assays (ELISAs). Over the course of this experiment, we determined that the expression level of these proteins changes specifically in the acute phase of KD, rather than the recovery phase of KD or other febrile illness. Thus, LRG1 could be used as biomarkers to facilitate KD diagnosis based on clinical features.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.